Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

- Top Line Data Expected soon after CEA Trial data reports in third quarter

-

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events (MACE) associated with inflammation, including heart attack and stroke.

"Completing enrollment in our second Phase 2 study is an important milestone for the company, and also represents the largest number of patients we have enrolled in a clinical trial to date," said Lawrence K. Cohen, PhD, chief executive officer of VIA Pharmaceuticals. "This trial will provide important data on VIA-2291's effect in the target population, patients with recent heart attack or unstable angina, and we remain on track to deliver data from this key trial later this year."

The ACS study, which enrolled 191 patients, is designed to establish dose and safety data in patients with ACS who have experienced a recent heart attack or unstable angina. The study includes measures of leukotrienes, biomarkers of inflammation, as well as medical imaging of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients i
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ("Perrigo") ... has completed the acquisition of leading OTC brands from ... million. The transaction is a clear demonstration of Perrigo,s ... leading European distribution network spanning 36 countries.  ... Papa commented, "We are excited to complete this ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015  Mylan ... its shareholders have approved Mylan,s proposed acquisition of ... and the related issuance of Mylan ordinary shares ... of shareholders held today. The transaction received the ... general meeting. In addition, the transaction received support ...
(Date:8/28/2015)... 28, 2015 The report "Eubiotics Market by Type ... Ruminant, and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends ... for Eubiotics was valued at USD 4.62 Billion in 2014 ... at a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President ... to increase acceptance of the chiropractic field in the military. All too often VA ... Although Chiropractic was made available to the VA program over a decade ago, the ...
(Date:8/29/2015)... ... 29, 2015 , ... Next weekend is Labor Day weekend, the last bash ... September 22nd this year). For IT security personnel, it should also mark the perfect ... far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/29/2015)... , ... August 29, 2015 , ... The popular television ... Earl Jones, recently announced that it will be devoting an entire short segment to ... millions of people around the globe on a daily basis, but recent advancements in ...
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Feb. 12 /PRNewswire-USNewswire/ - - A new report ... school students demonstrates the need for Congress to give ... regulate tobacco, Partnership for Prevention Interim President Corinne G. ... most-advertised brand of cigarettes in history is also the ...
... Feb. 12 Today, the Medicaid Health Plans ... focused on representing Medicaid health plans, applauded House and ... American Recovery and Reinvestment Act Conference Report that will ... "The Medicaid provisions in this agreement will allow states ...
... was released today by Every Child By Two:The U.S. ... debate over the causes of autism. The three ... combination with thimerosal-containing vaccines, does not cause autism. ... which have failed to show a link between vaccines ...
... Inc. (Nasdaq: IPHS ), a leading specialty ... of John M. Steitz to its Board of Directors. ... Officer of Albemarle Corporation, a leading global developer, manufacturer ... additives, catalysts and fine chemicals, a position he has ...
... doesn,t transfer to U.S., study finds , , THURSDAY, Feb. 12 ... tobacco can help smokers quit cigarettes, contends a new study. ... by using snus, a form of moist, powdered tobacco that,s ... among male smokers, and Swedish men have higher smoking cessation ...
... could lead to new treatments, researchers say , , THURSDAY, ... cure for the common cold. , Well, researchers are ... in that direction: the genetic codes of the 99 ... "There has been brilliant work done trying to synthesize ...
Cached Medicine News:Health News:Partnership for Prevention: CDC Report Shows Compelling Need for FDA Regulation of Tobacco 2Health News:Medicaid Health Plans of America Lauds Stimulus Bill's Conference Agreement Which Provides $90 Billion in Medicaid Relief for Nation's Most Vulnerable Citizens 2Health News:Federal Court Declares Vaccines Do Not Cause Autism 2Health News:Innophos Holdings, Inc. Elects John M. Steitz as New Independent Director 2Health News:Smokeless Tobacco May Not Help Smokers Quit 2Health News:Genetic Code of Common Cold Cracked 2Health News:Genetic Code of Common Cold Cracked 3
... 1027, with a Carbon Fiber Top, ... for superior C-arm access, safety and ... means C-Arm utilization is quick and ... is minimized resulting in a safer ...
A simple to use system which is both economical and ecologically friendly....
... The Amsco 3085 SP Surgical Table combines ... for patients weighing up to 1,000 lbs. ... patients in both normal and reverse orientation ... as with other patients.,The Amsco 3085 SP ...
... play an important part in our daily ... rheumatic changes can cause severe handicaps. A ... finger-joint prostheses was to produce a reconstructed ... function as nearly possible.,The cementless RM Finger ...
Medicine Products: